Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies

Journal of the American Society of Nephrology

Volumn 17, Issue 3, 2006, Pages 881-888

  Roos Van Groningen, Marian C ^a   Scholten, Eduard M ^a   Lelieveld, Patrick M ^a   Rowshani, Ajda T ^b   Baelde, Hans J ^a   Bajema, Ingeborg M ^a   Florquin, Sandrine ^c   Bemelman, Frederike J ^b   De Heer, Emile ^a   De Fijter, Johan W ^a   Bruijn, Jan A ^a   Eikmans, Michael ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Renal Transplant Unit   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALCINEURIN INHIBITOR; COLLAGEN; COLLAGEN ALPHA1; CYCLOSPORIN A; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; TSUKUBAENOLIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FIBROGENESIS; GRAFT SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; KIDNEY ALLOGRAFT; KIDNEY CORTEX; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION;

EID: 33645449993     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005080891     Document Type: Article

References (39)

1. Burke JF Jr, Pirsch JD, Ramos EL, Salomon DR, Stablein DM, Van Buren DH, West JC: Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med 331: 358-363, 1994
2. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 342: 605-612, 2000
3. Margreiter R: Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: A randomised multicentre study. Lancet 359: 741-746, 2002
4. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J: A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation 73: 775-782, 2002
5. Paul LC: Chronic renal transplant loss. Kidney Int 47: 1491-1499, 1995
6. Schweitzer EJ, Matas AJ, Gillingham KJ, Payne WD, Gores PF, Dunn DL, Sutherland DE, Najarian JS: Causes of renal allograft loss. Progress in the 1980s, challenges for the 1990s. Ann Surg 214: 679-688, 1991
7. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR: The natural history of chronic allograft nephropathy. N Engl J Med 349: 2326-2333, 2003
8. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M: Cyclosporine- associated chronic nephropathy. N Engl J Med 311: 699-705, 1984
9. Randhawa PS, Tsamandas AC, Magnone M, Jordan M, Shapiro R, Starzl TE, Demetris AJ: Microvascular changes in renal allografts associated with FK506 (tacrolimus) therapy. Am J Surg Pathol 20: 306-312, 1996
10. Paul LC: Chronic allograft nephropathy: An update. Kidney Int 56: 783-793, 1999
11. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63: 977-983, 1997
12. Islam M, Burke JF Jr, McGowan TA, Zhu Y, Dunn SR, McCue P, Kanalas J, Sharma K: Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. Kidney Int 59: 498-506, 2001
13. Shihab FS, Bennett WM, Tanner AM, Andoh TF: Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation 64: 1829-1837, 1997
14. Ninova D, Covarrubias M, Rea DJ, Park WD, Grande JP, Stegall MD: Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: Differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. Transplantation 78: 338-344, 2004
15. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E: Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 360: 361-364, 1992
16. Jain S, Furness PN, Nicholson ML: The role of transforming growth factor beta in chronic renal allograft nephropathy. Transplantation 69: 1759-1766, 2000
17. Ignotz RA, Massague J: Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 261: 4337-4345, 1986
18. Mohamed MA, Robertson H, Booth TA, Balupuri S, Kirby JA, Talbot D: TGF-beta expression in renal transplant biopsies: A comparative study between cyclosporin-A and tacrolimus. Transplantation 69: 1002-1005, 2000
19. Khanna A, Plummer M, Bromberek C, Bresnahan B, Hariharan S: Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 62: 2257-2263, 2002
20. Hetzel GR, Plum J, Ozcan F, Heering P, Grabensee B: Transforming growth factor-beta1 plasma levels in stable renal allograft recipients under different immunosuppression. Transplantation 71: 586-587, 2001
21. Matl I, Viklicky O, Voska L, Lodererova A, Vitko S: The effect of different immunosuppressive regimens on TGF-beta1 expression in kidney transplant patients. Transpl Int 18: 668-671, 2005
22. Bicknell GR, Williams ST, Shaw JA, Pringle JH, Furness PN, Nicholson ML: Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants. Br J Surg 87: 1569-1575, 2000
23. Baboolal K, Jones GA, Janezic A, Griffiths DR, Jurewicz WA: Molecular and structural consequences of early renal allograft injury. Kidney Int 61: 686-696, 2002
24. Miyagi M, Muramatsu M, Ishikawa Y, Ishii T, Sakai K, Arai K, Aikawa A, Ohara T, Mizuiri M, Hirayama N, Hasegawa A: Comparison of the therapeutic effects between CsA and FK506 on chronic renal allograft injury and TGF-beta expression. Transplant Proc 34: 1589-1590, 2002
25. Nicholson ML, Bailey E, Williams S, Harris KP, Furness PN: Computerized histomorphometric assessment of protocol renal transplant biopsy specimens for surrogate markers of chronic rejection. Transplantation 68: 236-241, 1999
26. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y: The Banff 97 working classification of renal allograft pathology. Kidney Int 55: 713-723, 1999
27. Eikmans M, Baelde HJ, de Heer E, Bruijn JA: Processing renal biopsies for diagnostic mRNA quantification: Improvement of RNA extraction and storage conditions. J Am Soc Nephrol 11: 868-873, 2000
28. Eikmans M, Baelde HJ, de Heer E, Bruijn JA: Effect of age and biopsy site on extracellular matrix mRNA and protein levels in human kidney biopsies. Kidney Int 60: 974-981, 2001
29. Koop K, Bakker RC, Eikmans M, Baelde HJ, de Heer E, Paul LC, Bruijn JA: Differentiation between chronic rejection and chronic cyclosporine toxicity by analysis of renal cortical mRNA. Kidney Int 66: 2038-2046, 2004
30. de Boer WI, Vermeij M, Diez de Medina SG, Bindels E, Radvanyi F, van der KT, Chopin D: Functions of fibroblast and transforming growth factors in primary organoid-like cultures of normal human urothelium. Lab Invest 75: 147-156, 1996
31. de Boer WI, Schuller AG, Vermey M, van der Kwast TH: Expression of growth factors and receptors during specific phases in regenerating urothelium after acute injury in vivo. Am J Pathol 145: 1199-1207, 1994
32. Bakker RC, Koop K, Sijpkens YW, Eikmans M, Bajema IM, de Heer E, Bruijn JA, Paul LC: Early interstitial accumulation of collagen type I discriminates chronic rejection from chronic cyclosporine nephrotoxicity. J Am Soc Nephrol 14: 2142-2149, 2003
33. Masseroli M, O'Valle F, Andujar M, Ramirez C, Gomez-Morales M, de Dios LJ, Aguilar M, Aguilar D, Rodriguez-Puyol M, Del Moral RG: Design and validation of a new image analysis method for automatic quantification of interstitial fibrosis and glomerular morphometry. Lab Invest 78: 511-522, 1998
34. Nicholson ML, McCulloch TA, Harper SJ, Wheatley TJ, Edwards CM, Feehally J, Furness PN: Early measurement of interstitial fibrosis predicts long-term renal function and graft survival in renal transplantation. Br J Surg 83: 1082-1085, 1996
35. Grimm PC, Nickerson P, Gough J, McKenna R, Stern E, Jeffery J, Rush DN: Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol 14: 1662-1668, 2003
36. Strutz F: The fibroblast-A (trans-)differentiated cell? Nephrol Dial Transplant 10: 1504-1506, 1995
37. Oleggini R, Musante L, Menoni S, Botti G, Duca MD, Prudenziati M, Carrea A, Ravazzolo R, Ghiggeri GM: Characterization of a DNA binding site that mediates the stimulatory effect of cyclosporin-A on type III collagen expression in renal cells. Nephrol Dial Transplant 15: 778-785, 2000
38. Scholten EM, Cremers SC, Schoemaker RC, Rowshani AT, van Kan EJ, den Hartigh J, Paul LC, de Fijter JW: AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 67: 2440-2447, 2005
39. Cremers SC, Scholten EM, Schoemaker RC, Lentjes EG, Vermeij P, Paul LC, den Hartigh J, de Fijter JW: A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients. Nephrol Dial Transplant 18: 1201-1208, 2003